It is well known that FGF23 circulating levels are upregulated in chronic kidney disease, and we have shown recently that FGF23 per se does not exert a pro-inflammatory effect on the “healthy” bronchial epithelium, whereas the COPD epithelium shows increases in IL-1β when stimulated with FGF23. This evidence concerns the gene IL1B and chronic obstructive pulmonary disease.